{"id":"sea-tgt","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04585815"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2023","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced N) — Carcinoma, Non-Small-Cell Lung. Trial terminated early."}],"aiSummary":"Sasanlimab is being studied in combination with targeted therapies, specifically Encorafenib and Binimetinib, for the treatment of advanced Non-small Cell Lung Cancer. Sasanlimab is also known as SEA-BCMA, but its exact mechanism of action is unknown.","brandName":"SEA-TGT","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"solution in vials","explanation":"The information needed to explain how SEA-TGT works was not provided in your request. To create an accurate explanation, please include: (1) the FDA-approved mechanism of action text, and (2) the approved indication(s). Once this information is provided, I can generate a comprehensive explanation of how this drug functions, its mechanism class, and its clinical applications.","oneSentence":"solution in vials","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"sea-tgt","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Carcinoma, Non-Small-Cell Lung","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04585815","phase":"discontinued","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced N","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":34,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2023-05","primaryEndpoint":"Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL4594496"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":2,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}